.png)
JHVEPhoto/iStock Editorial via Getty Images
- Phathom Pharmaceuticals (NASDAQ:PHAT) said that the U.S. FDA has updated its "Orange Book" to reflect that Voquezna (vonoprazan) new chemical entity exclusivity is valid through May 3, 2032.
- The exclusivity applies to both the 10 mg and 20 mg tablets.
English (US) ·